Hemangiosarcoma Awareness

A History of Hemangiosarcoma

When a family first hears the word hemangiosarcoma, it can feel as though they have stumbled onto something rare and unspoken, a disease that appeared out of nowhere and that no one was ready for. It can help, in a small way, to know that this is not a new illness, and not a neglected one. Hemangiosarcoma has been recognized, studied, and fought by veterinarians and scientists for the better part of a century. Knowing that history will not change what this cancer is. But it can offer a quiet kind of steadiness: the knowledge that many dedicated people have looked closely at this disease for a very long time, and that the work to understand it is, right now, moving faster than it ever has before.

This is the story of how we came to know hemangiosarcoma, told gently and honestly, including the long years when progress was painfully slow and the recent years that have brought real and growing hope.

A Cancer Named in the Middle of the Last Century

Hemangiosarcoma is a cancer connected to the blood vessels, and for that reason it has always been understood as a disease of the body's circulatory system. The first descriptions of the disease in dogs in the scientific literature date back to the 1950s and 1960s, according to a veterinary review of the cancer's biology. Those early reports appeared at almost the same time as the first medical accounts of angiosarcoma in people, the closely related and very rare human cancer, which was initially identified in workers exposed to certain industrial substances.

There is a poignant detail woven into this period of history. The same review notes that the growing medical attention to canine hemangiosarcoma coincided with the era when the role of dogs in human life was itself changing. Dogs were moving away from largely working lives, herding, guarding, and hunting, and into a new and tender place as members of the family. As dogs became companions whose health and comfort mattered deeply to the people who loved them, the diseases that affected them began, rightly and at last, to receive far closer attention.

The Breed Pattern Comes Into View

By the middle of the 1970s, one striking fact had become clear. Hemangiosarcoma was far more common in dogs than its counterpart was in people. Veterinary researchers found that the disease occurred in dogs at a rate roughly 25 to 100 times greater than angiosarcoma occurred in humans. This was not a rare curiosity to be noted and set aside. It was a genuinely common canine cancer, and it called for serious study.

Through the 1980s, the picture grew sharper. In 1980, researchers reported breed-associated risks for several cancers of the blood and blood vessels, hemangiosarcoma among them, drawing on the early veterinary medical databases of the time. By the end of that decade, clear breed predilections for the disease had been documented in both Europe and the United States. A landmark study in 1988 examined more than two hundred dogs with splenic disease and helped define the clinical and pathological features of splenic hemangiosarcoma, work still cited in veterinary references today. A few years later, in 1992, a similar effort described the skin-based forms of the disease in a large group of dogs.

One of the most sobering threads in this history concerns the Golden Retriever. As described in coverage of the breed's cancer research, a 1988 study from the University of Pennsylvania found that Golden Retrievers were neither more nor less likely than other dogs to develop cancer. Within a single decade, that had changed profoundly. A 1998 health survey by the Golden Retriever Club of America found that cancer accounted for a majority of deaths in the breed. The cancer burden now so strongly associated with Golden Retrievers is, in historical terms, a remarkably recent development, and that very recency is one of the clues researchers continue to follow today.

Decades of Slow and Difficult Progress

For much of the late twentieth century, progress against hemangiosarcoma was painfully slow, and it is only honest to say so plainly. The disease was difficult on every front. It hid until it was advanced. It spread early and widely through the body. And it resisted the treatments that medicine had to offer. By the year 2000, the standard of care had settled into a familiar pattern: surgery to remove the affected organ, followed by doxorubicin-based chemotherapy, an approach that could often buy precious time but rarely changed the final outcome. A veterinary review published at the turn of the millennium captured both the frustration and the hope of that moment, describing the limited success of existing treatments alongside a hopeful list of new approaches then beginning to be explored.

Part of the difficulty was a gap in the most fundamental understanding. A 2015 review of the disease's biology observed that, despite decades of diligent clinical research, advances against highly aggressive tumors like hemangiosarcoma had remained modest, and that a true understanding of the tumor's biology was still taking shape. It is hard to defeat what you do not yet fully understand, and for a long stretch of its history, hemangiosarcoma kept its most important secrets well guarded.

The Modern Era of Research

The last fifteen years have brought a genuine change of pace, and this is the most hopeful part of the story.

In June 2012, the Morris Animal Foundation launched the Golden Retriever Lifetime Study, the largest and most comprehensive study of its kind ever undertaken in veterinary medicine in the United States. Conceived by a team of veterinary leaders, the study enrolled more than three thousand Golden Retrievers across the country and committed to following them through their entire lives, gathering nutritional, environmental, genetic, and lifestyle information year after year. Its founders identified four cancers of special concern, and hemangiosarcoma was one of them.

What the study revealed about hemangiosarcoma was so striking that it reshaped the Foundation's priorities. The disease emerged as the leading cause of cancer death among the dogs in the study. In response, the Foundation created a dedicated Hemangiosarcoma Initiative, and in September 2023 announced funding for six new research studies devoted entirely to preventing, detecting, and treating the disease.

Real discoveries have followed. In 2024, researchers at the University of Minnesota reported a major finding about the very origin of the cancer. For decades, hemangiosarcoma had been assumed to arise straightforwardly from the mature cells that line the blood vessels. The new research suggested that the truth is more complex, a finding that helps explain why so many treatments designed to attack those vessel-lining cells had failed. Understanding where a cancer truly begins is one of the most important foundations for designing treatments that finally work.

Alongside this, genetic research has been steadily narrowing in on why certain dogs are so vulnerable. Using the rich data of the Golden Retriever Lifetime Study, researchers have applied genome-wide approaches to identify regions of canine DNA associated with hemangiosarcoma, work that continues to be refined. Other teams are now searching the study's stored biological samples for biomarkers that could one day allow the disease to be caught early, quietly, before it ever has the chance to cause a crisis.

There is one more reason this modern research carries meaning beyond dogs. Because canine hemangiosarcoma closely resembles the rare human cancer angiosarcoma, and because it is so much more common in dogs, what scientists learn from dogs may one day help people too. Researchers working with the Golden Retriever Lifetime Study have noted that lessons learned in dogs may help guide human research, given how similar the disease is in the two species. The dogs who have been part of this work are, in a quiet and real sense, helping to protect lives in ways their families could never have imagined.

Why This History Matters

For a family facing this diagnosis right now, history can feel like a distant and abstract thing. But there is something genuinely steadying in it. Hemangiosarcoma is not a mysterious new affliction, and it is not a forgotten one. It has been named, studied, and fought for roughly seventy years, by generation after generation of veterinarians and scientists who refused to look away from it. For much of that time, the progress was slow and the disappointments were many. But this present moment is different. More researchers, more funding, and better scientific tools are focused on hemangiosarcoma now than at any other point in its history, and the questions that matter most to families, how to find this cancer early and how to treat it well, are finally being asked with real urgency and real resources.

That is the shape of this history, and it is part of the reason a place like this exists. The dogs we have loved and lost are part of the story too. So is every family that chooses to learn, to share what they know with others, and to support the work still ahead. The history of hemangiosarcoma is still being written, and there is honest, well-founded hope in the pages still to come.

Sources and Further Reading

Return to Home